Skeletal muscle omics signatures in cancer cachexia: perspectives and opportunities.
Linda Anne GilmoreTraci L ParryGwendolyn A ThomasAndy V KhamouiPublished in: Journal of the National Cancer Institute. Monographs (2023)
Cachexia is a life-threatening complication of cancer that occurs in up to 80% of patients with advanced cancer. Cachexia reflects the systemic consequences of cancer and prominently features unintended weight loss and skeletal muscle wasting. Cachexia impairs cancer treatment tolerance, lowers quality of life, and contributes to cancer-related mortality. Effective treatments for cancer cachexia are lacking despite decades of research. High-throughput omics technologies are increasingly implemented in many fields including cancer cachexia to stimulate discovery of disease biology and inform therapy choice. In this paper, we present selected applications of omics technologies as tools to study skeletal muscle alterations in cancer cachexia. We discuss how comprehensive, omics-derived molecular profiles were used to discern muscle loss in cancer cachexia compared with other muscle-wasting conditions, to distinguish cancer cachexia from treatment-related muscle alterations, and to reveal severity-specific mechanisms during the progression of cancer cachexia from early toward severe disease.
Keyphrases
- papillary thyroid
- skeletal muscle
- squamous cell
- high throughput
- insulin resistance
- lymph node metastasis
- childhood cancer
- body mass index
- weight loss
- bariatric surgery
- stem cells
- squamous cell carcinoma
- advanced cancer
- small molecule
- early onset
- cardiovascular disease
- mesenchymal stem cells
- roux en y gastric bypass
- drug induced
- gastric bypass